Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous imatinib for COVID-19-induced ARDS
NL-OMON51903Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olaparib + durvalumab in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in extravascular lung water index. Started Aug 2021; status: active, not recruiting.
02
Drugs
olaparib + durvalumab
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51903.